Clinical trial NCT02776098: Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance
Official title: Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cystic Fibrosis
Keywords: Cystic Fibrosis
Glucose Intolerance
Muscle Accrual
Cystic Fibrosis-related Diabetes
Healthy Controls
Healthy Participants
Lead sponsor: Children's Hospital of Philadelphia
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: University of Pennsylvania
name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2016-05-18
Enrollment: 54
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This is longitudinal cohort study of 3 main study groups: CF subjects without CFRD, Healthy matched controls and CF subjects with newly diagnosed CFRD started on insulin therapy. Healthy controls without CF will be recruited and will be matched for age, sex, ethnicity, and body mass index (BMI) to CF subjects. Subjects with newly diagnosed CFRD will also be enrolled. This study will be carried out over a 5-year period.

CF subjects without CFRD (26) and healthy controls (26) will be followed annually for 2 years. CF subjects with newly diagnosed CFRD (10) will be followed for 6 months.

Brief summary: This study will investigate the link between glucose abnormalities and elements critical to muscle function including mass, composition and energy metabolism. the primary goal of the study is to determine whether Cystic Fibrosis (CF) disease is associated with muscle dysfunction, especially in the presence of glucose intolerance. This is a longitudinal cohort study of 3 main groups: CF subjects without Cystic Fibrosis-related diabetes (CFRD), healthy matched controls and CF subjects with newly diagnosed CFRD started on insulin therapy.

Detailed description: Cystic Fibrosis (CF) is a lethal inherited disease that primarily affects the lungs but also confers a high risk of diabetes, with up to 40-50% of adults experiencing Cystic Fibrosis-related diabetes (CFRD). CFRD is associated with an accelerated decline in lung function, nutritional status and survival and despite treatment mortality in patients with CFRD remains high. Airway inflammation and susceptibility to infections caused by hyperglycemia, and the catabolic effect of insulin deficiency are posited mechanisms of CFRD-associated morbidity. Respiratory failure caused by airway disease is well known but the contribution of respiratory muscle dysfunction may be critical. In Type 2 Diabetes Mellitus (T2DM) glucose and insulin defects are closely correlated with muscle function. The pulmonary muscles are crucial to respiration and airway clearance in CF. Muscle function is dependent on its mass, composition, and energy metabolism. Lean body mass (LBM) deficits are present in CF and improvement in LBM improves pulmonary function. Using T2DM as a model for muscle dysfunction, the study hypothesis is that glucose intolerance exacerbates LBM deficits, negatively affects muscle composition, and alters muscle metabolism leading to respiratory muscle dysfunction and a decline in pulmonary function.

CF subjects without CFRD and healthy controls will undergo 3 study visits (baseline then annually for 2 years) and CFRD subjects will undergo 2 study visits (baseline and 6 months after baseline). Evaluations will include neurologic exams, anthropometric assessments, 3-day dietary recall, MRI scans, oral glucose tolerance tests (CF subjects only), blood work, pulmonary function testing, muscle strength testing, exercise testing, bone density scans, and adverse event assessment.

Eligibility criteria: Inclusion Criteria for CF subjects without CFRD:

1. Males or females age 16 to 22 years.
2. Confirmed diagnosis of CF per CF Foundation guidelines
3. Parental/guardian permission (informed consent) and if appropriate, child assent.

Exclusion Criteria for CF subjects without CFRD

1. Chronic systemic glucocorticoid use e.g. for allergic bronchopulmonary aspergillosis
2. Organ transplantation
3. Forced Expiratory Volume (FFEV) 1%-predicted \< 40%
4. Established diagnosis of CFRD and treatment with insulin or hypoglycemic agent
5. Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
6. Pregnancy or breastfeeding (if female)
7. Pre-existing neurological or neuromuscular disease

All study visits for CF subjects will be scheduled during periods of baseline health. Visits will not be performed within 4 weeks of an acute respiratory illness or pulmonary exacerbation.

Inclusion Criteria for healthy controls

1. Age-, sex-, ethnicity-, and BMI-matched at time of enrollment to CF subjects without CFRD
2. Parental/guardian permission (informed consent) and if appropriate, child assent.

Exclusion Criteria for healthy controls

1. Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
2. Pregnancy or breastfeeding (if female)
3. Pre-existing neurological or neuromuscular disease

Inclusion Criteria for CF subjects with new CFRD

1. Males or females age 12 years or above.
2. Confirmed diagnosis of CF per CF Foundation guidelines.
3. New diagnosis of CFRD based on a) a clinically indicated Oral glucose tolerance test (OGTT) b) hyperglycemia (PG\>200 mg/dL) persisting \>48 hours and/or c) elevated HbA1C and within 4 weeks of starting insulin therapy.
4. Parental/guardian permission (informed consent) and if appropriate, child assent.

Exclusion Criteria for CF subjects with new CFRD

1. Chronic systemic glucocorticoid use e.g. for allergic bronchopulmonary aspergillosis
2. Organ transplantation
3. Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
4. Pregnancy or breastfeeding (if female)
5. Pre-existing neurological or neuromuscular disease

Primary outcomes:
measure: Compare change in mean lean body mass (LBM) from baseline to end of study
timeFrame: 24 months (CF without CFRD subjects & healthy controls); 6 months for CF subjects
Secondary outcomes:
measure: Compare Intramyocellular lipid (IMCL) accumulation from baseline to end of study
timeFrame: 24 months (CF without CFRD subjects & healthy controls); 6 months for CF subjects
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Children's Hospital of Philadelphia
state: Pennsylvania
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: Children's Hospital of Philadelphia
name: Clement L Ren, MD
role: PRINCIPAL_INVESTIGATOR
References: